Family Legacy Inc. Purchases New Shares in CVS Health Corporation $CVS

Family Legacy Inc. acquired a new stake in shares of CVS Health Corporation (NYSE:CVS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 9,377 shares of the pharmacy operator’s stock, valued at approximately $970,000.

Several other institutional investors and hedge funds have also recently modified their holdings of CVS. Norges Bank bought a new position in CVS Health in the fourth quarter worth about $1,666,265,000. Wellington Management Group LLP boosted its position in CVS Health by 193.2% during the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock valued at $1,473,270,000 after acquiring an additional 12,233,675 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of CVS Health by 1,020.7% during the 1st quarter. Pacer Advisors Inc. now owns 4,845,221 shares of the pharmacy operator’s stock worth $347,984,000 after acquiring an additional 4,412,882 shares during the period. Amundi raised its position in shares of CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after acquiring an additional 3,637,943 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of CVS Health by 44.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator’s stock valued at $446,703,000 after purchasing an additional 1,899,932 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Performance

Shares of CVS stock opened at $97.09 on Friday. The company has a market capitalization of $124.18 billion, a price-to-earnings ratio of 25.69, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a one year low of $67.42 and a one year high of $110.68. The company’s 50-day moving average is $102.52 and its 200 day moving average is $88.23.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. The business had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts expect that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.7%. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CVS shares. Morgan Stanley upped their price target on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. increased their price target on shares of CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a research note on Wednesday. Truist Financial lifted their price target on shares of CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Finally, Wells Fargo & Company upped their price objective on shares of CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Twenty-two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and a consensus price target of $106.75.

Insider Buying and Selling at CVS Health

In other news, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 3,372,000 shares of company stock valued at $317,473,598 in the last three months. 0.85% of the stock is owned by insiders.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.